On the 20th, TaiMed Biologics announced the formal signing of an exclusive sales and marketing agreement for the HIV drug Trogarzo in Taiwan with Orient Europharma . The specific licensing terms were not disclosed due to confidentiality agreements. Under the contract, Orient Europharma will be responsible for Trogarzo's drug registration, product promotion, and commercialization in Taiwan.
Established in 1982, Orient Europharma was listed on the Taiwan Stock Exchange in 2003. With over 1,000 employees globally, more than 40% of whom are overseas, the company owns two pharmaceutical factories, Yulin and Yuxing. Orient Europharma's product line includes prescription drugs, innovative medical products, infant and child health care, adult nutrition supplements, and medical aesthetics, making it a comprehensive multinational pharmaceutical company.
Trogarzo is aggressively expanding its global presence. TaiMed Biologics stated that in addition to its current sales focus in the United States, it has signed exclusive sales and marketing agreements with AcedrA and Five Continents Pharmaceuticals for the Middle East, North Africa, and Hong Kong-Macau regions this year. TaiMed Biologics indicated that expanding into the Taiwanese market will help broaden Trogarzo's user base, thus enhancing the company's future revenue.
Orient Europharma emphasized that signing the exclusive sales and marketing agreement with TaiMed Biologics for the HIV drug Trogarzo in Taiwan will lead to drug registration, product promotion, and commercialization responsibilities, contributing to future revenue growth.
Trogarzo (ibalizumab-uiyk) represents a breakthrough in HIV treatment. TaiMed Biologics stated that it is the world's first long-acting monoclonal antibody approved for HIV treatment. By binding to the CD4 receptor and blocking viral entry, it acts as a post-attachment inhibitor of HIV-1 virus, preventing virus invasion of CD4+ immune cells. Proudly, Trogarzo is the first and currently the only monoclonal antibody approved for HIV treatment in the United States and European countries and regions. When used in combination with other antiretroviral drugs, it is applicable to adults with multidrug-resistant (MDR) HIV-1 infection and experience with failed HIV drug therapy. Trogarzo has been approved for intravenous administration every two weeks via infusion or injection.
Resource (mandarin):
